Ország: Új-Zéland
Nyelv: angol
Forrás: Medsafe (Medicines Safety Authority)
Lidocaine hydrochloride monohydrate 10.66 mg/mL equivalent to Lidocaine hydrochloride 10.0 mg/ml
Baxter Healthcare Ltd
Lidocaine hydrochloride monohydrate 10.66 mg/mL (= Lidocaine hydrochloride 10.0 mg/ml)
1% w/v
Solution for injection
Active: Lidocaine hydrochloride monohydrate 10.66 mg/mL equivalent to Lidocaine hydrochloride 10.0 mg/ml Excipient: Hydrochloric acid Nitrogen Sodium chloride Sodium hydroxide Water for injection
Ampoule, glass, 5ml clear, Ph. Eur. Type 1, in blister sheets of 5 ampoules in carton of 5 sheets, 25 dose units
Prescription
Prescription
Moehs Catalana SL
Lidocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: local infiltration; minor or major nerve blocks; epidural block; arthroscopy; intravenous regional anaesthesia.
Package - Contents - Shelf Life: Ampoule, glass, 5ml clear, Ph. Eur. Type 1, in blister sheet of 5 ampoules packed in carton - 5 dose units - 48 months from date of manufacture stored at or below 25°C. Do not refrigerate or freeze - Ampoule, glass, 5ml clear, Ph. Eur. Type 1, in blister sheets of 5 ampoules in carton of 5 sheets - 25 dose units - 48 months from date of manufacture stored at or below 25°C - Ampoule, glass, 2ml clear, Ph. Eur. Type 1, in blister sheets of 5 ampoules in carton of 5 sheets - 25 dose units - 48 months from date of manufacture stored at or below 25°C - Vial, glass, 20 ml clear Ph. Eur Type 1, grey bromobutyl stopper unit packed in carton - 1 dose units - 48 months from date of manufacture stored at or below 25°C - Vial, glass, 20 ml clear Ph. Eur Type 1, grey bromobutyl stopper unit packed in carton - 5 dose units - 48 months from date of manufacture stored at or below 25°C
2012-01-24
NEW ZEALAND DATA SHEET LIDOCAINE‐BAXTER Data Sheet 11 March 2020 Page 1 of 13 Baxter Healthcare Ltd 1 LIDOCAINE‐BAXTER (solution for infusion) Lidocaine‐Baxter 1% w/v solution for injection. Lidocaine‐Baxter 2% w/v solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION _Active ingredient _ Lidocaine‐Baxter 1% w/v: Lidocaine hydrochloride monohydrate 10.66mg/mL (= Lidocaine hydrochloride 10.0mg/mL). Lidocaine‐Baxter 2% w/v: Lidocaine hydrochloride monohydrate 21.32mg/mL (= Lidocaine hydrochloride 20.0mg/mL). Note: Lidocaine is another name for lignocaine. Lidocaine is mostly used in this document.For the full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. _Appearance _ Lidocaine‐Baxter is a clear, colourless, particle‐free, sterile, isotonic, pH adjusted solution of Lidocaine hydrochloride Ph Eur conforming to Lidocaine Injection BP. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Lidocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: local infiltration; minor or major nerve blocks; epidural block; arthroscopy; intravenous regional anaesthesia. 4.2 Dose and method of administration _Adults and children above 12 years _ The following table is a guide to dosage for the more commonly used techniques in the average adult. The figures reflect the expected average dose range needed. Standard textbooks should be consulted for factors affecting specific block techniques and for individual patient requirements. The clinician's experience and knowledge of the patient's physical status are of importance in calculating the required dose. The lowest dose required for adequate anaesthesia should be used (see section 4.4). Individual variations in onset and duration occur. Table 1 Dosage recommendations Type of block Concentration (mg/mL) Dose Onset (min) Duration of effect (h) (mL) (mg) SURGICAL ANAESTHESIA Lumbar epidural administration [1] 20 15 to 25 300 to 500 15 to 20 1.5 to 2 Thoracic epidural admi Olvassa el a teljes dokumentumot